β2-Агонисты короткого действия: особенности применения при хронических обструктивных заболеваниях легких
β2-Агонисты короткого действия: особенности применения при хронических обструктивных заболеваниях легких
Княжеская Н.П., Динер Н.Е. β2-Агонисты короткого действия: особенности применения при хронических обструктивных заболеваниях легких. Consilium Medicum. 2008; 10 (10): 41–45.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–26.
2. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. М.: Атмосфера, 2002.
3. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии b2-адреностимуляторов. Рус. мед. журн. 2001; 9 (21): 930–3.
4. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence based guidelines: American College of Chest Physicians/American Collegeof Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
5. Fink JB, Rubin BK. Problems with Inhaler Use: a Call for improved Clinican and Patient Education. Respir Care 2005; 50 (10): 1360–74.
6. Hall Ian P. b2-Adrenoreceptor agonists. In: Barnes P.J.: Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed., CopyrightC 2002, Academic Press.
7. June D. Achieving to change: challenges and successes in the formulation of CFC-free MDIs. Eur Respir Rev 1997; 7 (41): 32–4.
8. Lenney J, Inns JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation device. Respir Med 2000; 94: 496–500.
9. Liggett SB. Polymorphisms of the β2–adrenergic receptor in asthma. Am J Respir Cri Care Med 1997; 156: 156–62.
10. Lipworth BJ, Hall IP, Tan S et al. Effects of genetic polymorphism on ex vivo and in vivo function of β2–adrenoceptors in asthmatic patients. Chest 1999; 115: 324–8.
11. Lipworth BJ, Kopelman GH, Wheatley AP et al. β2-Adrenoceptor promoter polymorphism: extended halotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57: 61–6.
12. Matthys H. CFCs and their effect on the ozone layer: the Montreal Protocol and consequences for physicians. Eur Respir Rev 1997; 7 (41): 29–31
13. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–7.
14. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40–7.
15. Rau GL. Practical Problems with Aerosol Therapy in COPD. Respir Care 2006; 51 (2): 158–72.
16. Rubin BK, Fink JB. Optimizing Aerosol Delivery by Pressurized Metered-Dose Inhalers. Respir Care2005; 50 (9): 1191–7.
2. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. М.: Атмосфера, 2002.
3. Цой А.Н., Архипов В.В. Вопросы клинической фармакологии b2-адреностимуляторов. Рус. мед. журн. 2001; 9 (21): 930–3.
4. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence based guidelines: American College of Chest Physicians/American Collegeof Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
5. Fink JB, Rubin BK. Problems with Inhaler Use: a Call for improved Clinican and Patient Education. Respir Care 2005; 50 (10): 1360–74.
6. Hall Ian P. b2-Adrenoreceptor agonists. In: Barnes P.J.: Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed., CopyrightC 2002, Academic Press.
7. June D. Achieving to change: challenges and successes in the formulation of CFC-free MDIs. Eur Respir Rev 1997; 7 (41): 32–4.
8. Lenney J, Inns JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation device. Respir Med 2000; 94: 496–500.
9. Liggett SB. Polymorphisms of the β2–adrenergic receptor in asthma. Am J Respir Cri Care Med 1997; 156: 156–62.
10. Lipworth BJ, Hall IP, Tan S et al. Effects of genetic polymorphism on ex vivo and in vivo function of β2–adrenoceptors in asthmatic patients. Chest 1999; 115: 324–8.
11. Lipworth BJ, Kopelman GH, Wheatley AP et al. β2-Adrenoceptor promoter polymorphism: extended halotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57: 61–6.
12. Matthys H. CFCs and their effect on the ozone layer: the Montreal Protocol and consequences for physicians. Eur Respir Rev 1997; 7 (41): 29–31
13. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–7.
14. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40–7.
15. Rau GL. Practical Problems with Aerosol Therapy in COPD. Respir Care 2006; 51 (2): 158–72.
16. Rubin BK, Fink JB. Optimizing Aerosol Delivery by Pressurized Metered-Dose Inhalers. Respir Care2005; 50 (9): 1191–7.
Авторы
Н.П.Княжеская, Н.Е.Динер
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.